ClinicalTrials.gg
RecruitingNCT06176183Updated Aug 28, 2025

A Comparative Prospective Study of the Arthroscopic Meniscal Repair Methods

An interventional study of Arthroscopic meniscus repair in Meniscus Tear Caused by a Traumatic Event, Fibrin Clot Augmentation and Meniscal Repair, sponsored by Vilnius University. Recruiting at 2 sites in Lithuania. Open to participants aged 0 Years to 19 Years. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Vilnius University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 2 years 6 months after the study started (first participant enrolled May 2021, registered Dec 2023).
  • Started May 2021; still recruiting 5 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
0 Years to 19 Years
Sex
All
01

Study summary

Performing arthroscopic meniscus repair following a traumatic meniscus tear as an alternative to a meniscectomy is now an acceptable choice. Preserving meniscus tissues is crucial due to the significant role they play as an essential part of the knee joint. It is essential to comprehend the additional tools that can impact the recovery of the meniscus after suturing. Patients have been randomly assigned into two groups using the computer "www.randomiser.org," and the treatment outcomes were compared after one year. One group of patients has received a standard meniscus suturing technique, whereas another group has experienced the meniscus suturing treatment with an additional fibrin clot approach. Data pertaining to demographics, clinical characteristics, radiological findings, and survey responses have been carefully collected prospectively.

02

Conditions studied

  • Meniscus Tear Caused by a Traumatic Event
  • Fibrin Clot Augmentation
  • Meniscal Repair

Keywords

  • meniscal tear
  • meniscal repair
  • fibrin clot
  • augmentation
  • arthroscopy
  • knee
  • young patients
03

In context

Lead sponsor

Vilnius University is the lead sponsor of 61 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who provide consent to participate in the study, including patients and their care providers. The inclusion criteria for this study are as follows: being under the age of 19, having a traumatic isolated full-thickness meniscal tear longer than 1cm that has been confirmed by both preoperative MRI and arthroscopy, and not having undergone any previous surgery on the affected knee.

Exclusion criteria

Exclusion Criteria:

  • This investigation excludes patients with developmental disabilities who are unable to read or interpret in their native language.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Cohort I of patients

    Individuals who undergo the conventional arthroscopic meniscus repair procedure

    Procedure: Arthroscopic meniscus repair

  • Other
    Cohort II of patients

    Patients who receive the supplementary fibrin clot augmentation during the arthroscopic meniscus repair operation.

    Procedure: Arthroscopic meniscus repair

Interventions

  • ProcedureArthroscopic meniscus repair

    A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the "all-inside" or "outside-inside" and "inside-outside" techniques. If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted.

    Also known as: Arthroscopic meniscus repair with fibrin clot augmentation

06

What researchers measure

Primary outcomes

  1. Pediatric International Documentation Committee Subjective (Pedi-IKDC) Knee Form.

    Pedi-IKDC is used to measure knee-related symptoms, function, and sports activity among children. The questionnaire consists of 13 items, each of which is scored using one of three rating systems: a range of 0 to 10 for items 2, 3, 12, and 13, a range of 0 to 4 for items 1, 4, 5, 6, 9, and 10, and a range of 0 to 1 for items 7 and 8. The 11th item consists of nine subquestions, each of which can be scored from 0 to 4. The overall score value is calculated by adding only the responses to 12 items and dividing the total by 92 (the highest number of points attainable). The score runs from 0 (worst case scenario) to 100 (best case scenario). The Pedi-IKDC has been proven to be a valid, trustworthy, and responsive questionnaire in a paediatric population with varied knee disorders, especially ligament and meniscal injuries, joint instability, and other disorders

    Time frame: before treatment, after 12 months and 24 months following treatment

  2. Lysholm knee scale

    Lysholm knee scoring scale has been proven to be suitable for a variety of knee pathologies and also for the adolescent population. The scale comprises eight items. Higher values of the score indicate better functioning of the knee. (range from 0 to 100).

    Time frame: before treatment, after 12 months and 24 months following treatment

  3. Health-related paediatric quality of life (PedsQL)

    PedsQL is a generic score, which estimates the quality of life of paediatric patients. The questionnaire consists of four domains with 23 questions: the general physical functioning, emotional, social, and functioning at school domains

    Time frame: before treatment, after 12 months and 24 months following treatment

Secondary outcomes

  1. Clinical evaluation at 12 and 24 months postoperatively. The clinical assessment involves evaluating of pain, swelling and estimating and comparing the range of motion of the knee with the contralateral side.

    All patients are evaluated

    Time frame: 12 and 24 months postoperatively.

  2. magnetic resonance imaging (MRI scan) of the knee

    1.5T MRI system. Four main diagnostic sequences were analyzed, including sagittal proton density fast spin echo (PD FS-Sag), sagittal T2-weighted fast spin echo (T2W-Sag), coronal proton density fast spin echo with fat saturation (PD FS-Cor), and coronal T2-weighted fast spin echo with fat saturation (T2W-Cor). Signal changes on MRI are graded using Stoller and Crues' 3-stage classification. Grade 0 was defined as a normal meniscus; the meniscus demonstrates low signal intensity in the images. Grade 1 is described as an intrameniscal signal with irregular margins that do not connect or communicate with an articular surface. Grade 2 is defined as a linear signal that does not abut or communicate with an articular surface. A linear or complex signal intensity that abuttes or communicates with an articular surface is classified as Grade 3. In summary, grade 3 is deemed unhealed, grade 2 as partially healed, and grade 1 as fully healed due to MRI assessment.

    Time frame: before treatment, after 12 months and 24 months following treatment

  3. Revision rates (secondary arthroscopies)

    secondary arthroscopies (revision) at 12 and 24 month following primary surgery

    Time frame: 12 and 24 month following primary surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — As per the study protocol, the IPD has no intention of disclosing the information to third parties or other researchers. In accordance with the data analysis and verification process, the main author of the research could be requested for the provision of anonymized data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Sep 2025, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2023
First posted
Dec 19, 2023
StartActual
May 26, 2021
Primary completionEst.
Sep 26, 2025
CompletionEst.
Dec 26, 2026
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06176183
Lead sponsor
Vilnius University
Collaborators
Vilnius University Hospital Santaros Klinikos
Responsible party
Viktorija Brogaite (Viktorija Brogaite Martinkeniene MD, Vilnius University) — Principal investigator
First posted
Dec 19, 2023
Start date
May 26, 2021
Primary completion
Sep 26, 2025 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Aug 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion